Login
$PMVP
$1.15 -$0.04 (3.28%) After hours

$PMVP SEC Filings

Filed On Filing
10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

Pivotal Phase 2 rezatapopt PYNNACLE data to be featured in late-breaking oral presentation at ENA 2026

05 Oct 2026 Form 4: Eckler Matthew Joseph, Director

Granted 84,000 Stock Option (right to buy)

05 Oct 2026 Form 3: Eckler Matthew Joseph, Director

No securities owned

05 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Dr. Eckler brings more than two decades of combined experience in healthcare investing across public and private markets at Samsara BioCapital, ArrowMark, and GMT Capital, and scientific research

15 Sep 2026 SCHEDULE 13G
02 Sep 2026 8-K: Entry into a Material Definitive Agreement; Other Events

As representative (the “Representative”) of the several Underwriters

02 Sep 2026 424B5
31 Aug 2026 424B3
31 Aug 2026 424B5
31 Aug 2026 8-K: Other Events

PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

14 Aug 2026 10-Q
14 Aug 2026 8-K: Results of Operations and Financial Condition

Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed

28 Jul 2026 SCHEDULE 13G/A
10 Jul 2026 SCHEDULE 13G/A
05 Jun 2026 Form 4: Stelzer Laurie, Director

Granted 42,000 Stock Option (right to buy)

05 Jun 2026 Form 4: Levine Arnold J, Director

Granted 42,000 Stock Option (right to buy)

05 Jun 2026 Form 4: Gallagher Carol Giltner, Director

Granted 42,000 Stock Option (right to buy) · Gave 42,000 Stock Option (right to buy) as a gift · Acquired 42,000 Stock Option (right to buy) (Gift)

05 Jun 2026 Form 4: Flowers Kirsten, Director

Granted 42,000 Stock Option (right to buy)

05 Jun 2026 Form 4: Baum Charles M, Director

Granted 42,000 Stock Option (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support